Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

2003, Effects of different blood pressure lowering regimens on major cardiovascular events: second cycle of prospectively designed overviews., Lancet, 362, 1527, 10.1016/S0140-6736(03)14739-3

Pfeffer, 2003, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM–Overall programme, Lancet, 362, 759, 10.1016/S0140-6736(03)14282-1

Dickstein, 2002, Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial, Lancet, 360, 752, 10.1016/S0140-6736(02)09895-1

Pitt, 2000, Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II, Lancet, 355, 1582, 10.1016/S0140-6736(00)02213-3

Williams, 2005, Recent hypertension trials: implications and controversies, J Am Coll Cardiol, 45, 813, 10.1016/j.jacc.2004.10.069

2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients., N Engl J Med, 342, 145, 10.1056/NEJM200001203420301

Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3

1998, Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments., J Hypertens, 16, 127

Nissen, 2004, Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial, JAMA, 292, 2217, 10.1001/jama.292.18.2217

Marre, 2004, Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study), BMJ, 328, 495, 10.1136/bmj.37970.629537.0D

2003, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)., Lancet, 362, 782, 10.1016/S0140-6736(03)14286-9

MacMahon, 2000, Randomized, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2. Collaborative Research Group. Prevention of Atherosclerosis with Ramipril, J Am Coll Cardiol, 36, 438, 10.1016/S0735-1097(00)00736-1

2004, Angiotensin-converting enzyme inhibition in stable coronary artery disease., N Engl J Med, 351, 2058, 10.1056/NEJMoa042739

2001, Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack., Lancet, 358, 1033, 10.1016/S0140-6736(01)06178-5

Teo, 2000, Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT), Circulation, 102, 1748, 10.1161/01.CIR.102.15.1748

Wright, 2002, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial, JAMA, 288, 2421, 10.1001/jama.288.19.2421

2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic., JAMA, 288, 2981, 10.1001/jama.288.23.2981

Wing, 2003, A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly, N Engl J Med, 348, 583, 10.1056/NEJMoa021716

Hansson, 1999, Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial, Lancet, 353, 611, 10.1016/S0140-6736(98)05012-0

Hansson, 1999, Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension 2 study, Lancet, 354, 1751, 10.1016/S0140-6736(99)10327-1

1998, Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39., BMJ, 317, 713, 10.1136/bmj.317.7160.713

Estacio, 1998, The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension, N Engl J Med, 338, 645, 10.1056/NEJM199803053381003

Schrier, 2002, Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes, Kidney Int, 61, 1086, 10.1046/j.1523-1755.2002.00213.x

Yui, 2004, Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases B (JMIC-B) randomized trial, Hypertens Res, 27, 181, 10.1291/hypres.27.181

Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303

Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161

Lithell, 2003, The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial, J Hypertens, 21, 875, 10.1097/00004872-200305000-00011

Julius, 2004, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial, Lancet, 363, 2022, 10.1016/S0140-6736(04)16451-9

McMurray, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM–Added trial, Lancet, 362, 767, 10.1016/S0140-6736(03)14283-3

Granger, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM–Alternative trial, Lancet, 362, 772, 10.1016/S0140-6736(03)14284-5

Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM–Preserved Trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7

Cohn, 2001, A randomised trial of the angiotensin-receptor blocker Valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713

Warnica, 2001, Ischemia Management with Accupril past bypass Graft via Inhibition of angiotensin coNverting Enzyme (IMAGINE): a multicentre randomized trial-design and rationale, Can J Cardiol, 87, 1058

Pitt, 2001, The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function, Am J Cardiol, 87, 1058, 10.1016/S0002-9149(01)01461-8

2000, Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)., JAMA, 283, 1967, 10.1001/jama.283.15.1967

Agodoa, 2001, Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis:a randomized controlled trial, JAMA, 285, 2719, 10.1001/jama.285.21.2719

Pfeffer, 2003, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, N Engl J Med, 349, 1893, 10.1056/NEJMoa032292

Messerli, 2002, If only cardiologists did properly measure blood pressure. Blood pressure recordings in daily practice and clinical trials, J Am Coll Cardiol, 40, 2201, 10.1016/S0735-1097(02)02607-4

McDonald, 2005, Angiotensin receptor blockers and risk of myocardial infarction: systematic review, BMJ, 331, 873, 10.1136/bmj.38595.518542.3A

Volpe, 2005, Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds, J Hypertens, 12, 2113, 10.1097/01.hjh.0000194114.12228.16

Verma, 2004, Angiotensin receptor blockers and myocardial infarction, BMJ, 329, 1248, 10.1136/bmj.329.7477.1248

2000, Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials., Lancet, 356, 1955, 10.1016/S0140-6736(00)03307-9

Teo, 2004, Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials, Am Heart J, 148, 52, 10.1016/j.ahj.2004.03.020

Gradman, 2005, Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients, Circulation, 111, 1012, 10.1161/01.CIR.0000156466.02908.ED